Disseminated mucormycosis demands immediate, coordinated treatment. When patients have pre-existing renal failure, the choice of systemic antifungal agent is directly shaped by that impairment — and evidence supports specific agents that remain effective in this setting.
Pre-existing renal failure is a key factor determining which antifungal agents are appropriate. Evidence shows that certain azole-class antifungals are effective in patients with renal impairment, making them the agents of choice in this scenario.
Management involves early surgical intervention — complete debridement with clean margins where feasible — combined with immediate systemic antifungal therapy. In the setting of pre-existing renal failure, an azole-class antifungal is used in place of conventional alternatives.
The clinical goal is stable disease or partial response, defined by resolution of signs and symptoms of infection and substantial radiographical improvement. Given the rapid progression of mucormycosis, response is assessed by weekly imaging.